A CB1 Mutation Delayed THC Tolerance in a Heat-Pain Test in Males, Not Females
A receptor mutation did not alter THC tolerance identically in male and female mice. A result described simply as a genetic resistance to tolerance would miss both the sex and endpoint restrictions.
Testing receptor desensitization
Researchers compared mice carrying the S426A/S430A CB1 receptor mutation with wild-type littermates. They assessed pain-related responses and body temperature after THC and the experimental cannabinoid agonist CP55,940. These were preclinical measures, not clinical pain scores.
Acute sensitivity and tolerance differed
The mutation enhanced acute antinociceptive responses to both agonists in both sexes. However, it conferred partial resistance to antinociceptive tolerance to THC in males, without the same effect in females. It did not provide the corresponding protection against CP55,940 tolerance.
The temperature result was also limited
The mutation did not alter tolerance to the hypothermic effects in either sex. Thus, an enhanced initial response did not imply reduced adaptation on every later measure. Pain-related behavior and thermoregulation were separate outcomes.
Why this cannot serve as a personal predictor
The experiment used engineered mice, selected doses and specific pain tests. It does not establish a human genetic test for cannabis tolerance, a dose recommendation or preserved driving ability. Other disease models and cannabinoid agonists can recruit different pathways. The study supports naming the sex, challenge drug and endpoint before generalizing a proposed tolerance mechanism.
Related analysis: evaluating cannabis tolerance claims.
Primary research
Henderson-Redmond AN; Sepulveda DE; Ferguson EL; Kline AM; Piscura MK; Morgan DJ. Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ9-THC). Psychopharmacology (2022). DOI: 10.1007/s00213-021-05886-9.
